CLAIMS

1. An oligomeric compound comprising three regions:

i) a first region (region A), which is an antisense oligomer of 10 – 22 contiguous nucleotides complementary to a nucleic acid target, wherein the first region is a gapmer;

ii) a second region (region B) which comprises between 1 – 10 nucleotides, which is covalently linked to the 5' or 3' nucleotide of the first region, such as via a internucleoside linkage group such as a phosphodiester linkage, wherein either

a. the internucleoside linkage between the first and second region is a phosphodiester linkage and the nucleoside of the second region adjacent to the first region is either DNA or RNA; and/or

b. at least 1 nucleoside of the second region is a phosphodiester linked DNA or RNA nucleoside;

iii) a third region which comprises a conjugate moiety, a targeting moiety, a reactive group, or a blocking moiety, wherein the third region is covalent linked to the second region.

2. The oligomer according to claim 1, wherein the internucleoside linkages of the first region comprise at least one internucleoside linkage other than phosphodiester, such as at least one, such as at least 50%, such as at least 75%, such as at least 90%, such as 100% of the internucleoside linkages in region A are other than phosphodiester.

3. The oligomer according to claim 1 or 2, wherein the internucleoside linkages other than phosphodiester are sulphur containing internucleoside linkages, such as phosphorothioate, phosphorodithioate and boranophosphate, such as phosphorothioate.

4. The oligomer according to any one of claims 1 to 3, wherein the nucleic acid target is selected from the group consisting of ApoB, PCSK9, miR-122, FVII, FXI, ApoCII, Apo(a), HBV, ANGPTL3, GCGR, FGFR4, DGAT-2, GCCR, Complement component C5, AAT, TTR, ALAS-1, and VEGF.

5. The oligomer according to any one of claims 1 to 4, wherein the first region comprises at least one bicyclic nucleotide analogue (LNA).

6. The oligomer according to any one of claims 1 – 5, wherein the first region and the second region form a contiguous nucleotide sequence.

7. The oligomer according to any one of claims 1 – 6, wherein the second region is 5’ to the first region.

8. The oligomer according to any one of claims 1 – 6, wherein the second region is 3’ to the first region.

9. The oligomer according to claim 7 or 8, wherein the first region is covalently linked to the second region via a phosphodiester linkage.

10. The oligomer according to any one of claims 1 - 9, wherin the second region is 1 to 4 nucleotides long.

11. The oligomer according to any one of claims 1 – 9, wherein the second region comprises at least two, such as at least three consecutive nucleoside units, selected from the group of DNA and RNA units that are linked by phosphodiester linkages.

12. The oligomer according to any one of claims 1 – 11, wherein the second region comprises more than one nucleoside and the linkage group(s) between the 2 nucleosides adjacent to region A are phosphodiester linkages.

13. The oligomer according to any one of claims 1 – 12, wherein the second region is covalently linked to the third region at the terminal nucleoside of the second region (i.e. the 3’ or 5’ terminus, depending on the position of the first region).

14. The oligomer according to claim 13, wherein the third region is covalently linked to the second region via a phosphodiester linkage.

15. The oligomer according to any one of claims 1 – 14, wherein the oligomeric compound comprises at least two phosphodiester groups, wherein the first linkage is between the first and the second region and the other is positioned between the second and third regions, optionally between a linker group and the second region.

16. The oligomer according to claim 15, wherein the second region consists of one linked DNA or RNA.

17. The oligomer according to any one of claims 1 – 16, wherein the third region comprises a non-nucleotide moiety, such as a conjugate group, such as a sterol, for example cholesterol, or a carbohydrate, such as GalNAc/GalNAc cluster.

18. The oligomer according to claim 17, wherein the third region comprises a moiety selected from the group consisting of: a lipophilic group (e.g. a lipid, a fatty acid, a sterol), a protein, a peptide, an antibody or fragment thereof, a polymer, a reporter group, a dye, a receptor ligand, a small molecule drug, a prodrug, and a vitamin.

19. The oligomer according to any one of claims 1 – 16, wherein the third region comprises a nucleic acid or polymer thereof, such as an aptamer, or a blocking nucleotide sequence.

20. The oligomer according to any one of claims 1 – 19, wherein the third region comprises a targeting group.

21. The oligomer according to any one of claims 1 – 16, wherein the third region comprises an activated group.

22. A pharmaceutical composition comprising the oligomeric compound of any one of claims 1 - 21, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

23. The oligomeric compound according to any one of claims 1 – 21 for use in the inhibition of a nucleic acid target in a cell.

24. The oligomeric compound according to any one of claims 1 – 21 for use in the treatment of a medical disease or disorder.

25. The oligomeric compound for the use according to claim 24, wherein the disease or disorder is hypercholesterolemia, hyperlipidemia, HCV or HBV.